Try a new search

Format these results:

Searched for:

person:caplaa01

Total Results:

1359


Joseph J. Fins' Rights Come to Mind: Brain Injury, Ethics and the Struggle for Consciousness

Caplan, Arthur L
The book reflects Fins' role as co-director of the Consortium for the Advanced Study of Brain Injury at Weill Cornell Medicine and the Rockefeller University and his struggle to answer the kinds of questions that stand to shape how society treats people with brain injuries. What is the capacity of brains to recover? What are the mechanisms of that recovery? How do we know that our assessments are accurately describing what's going on in a patient's mind? And what does society morally owe these patients and families?
PMCID:6132041
PMID: 30210658
ISSN: 1524-6205
CID: 3286892

How can aging be thought of as anything other than a disease?

Chapter by: Caplan, Arthur
in: Handbook of the Philosophy of Medicine by
[S.l.] : Springer Netherlands, 2017
pp. 233-240
ISBN: 9789401786874
CID: 3031062

Germline gene therapy is compatible with human dignity [Letter]

Sykora, Peter; Caplan, Arthur
PMCID:5709747
PMID: 29141985
ISSN: 1469-3178
CID: 2785242

Extending Ethical Strides: From Tribal IRBs to the Bronx Community Research Review Board

Friesen, Phoebe; Kearns, Lisa; Redman, Barbara K; Caplan, Arthur L
PMID: 29111932
ISSN: 1536-0075
CID: 2772042

Hard Choices for Vulnerable Patients: Some Lessons Learned That May Apply

Kearns, Lisa; Caplan, Arthur L
PMID: 29020543
ISSN: 1536-0075
CID: 2731662

The Council of Europe should not reaffirm the ban on germline genome editing in humans

Sykora, Peter; Caplan, Arthur
PMCID:5666594
PMID: 28986351
ISSN: 1469-3178
CID: 2720092

Ethical lessons from a tale of two genetically modified insects

Neuhaus, Carolyn P; Caplan, Arthur L
PMID: 28787406
ISSN: 1546-1696
CID: 2663862

The Ethics of Open-Label Placebos in Pediatrics

Trogen, Brit; Caplan, Arthur; Klass, Perri
PMID: 28771409
ISSN: 1098-4275
CID: 2655902

Characterizing expanded access and compassionate use programs for experimental drugs

Miller, Jennifer E; Ross, Joseph S; Moch, Kenneth I; Caplan, Arthur L
OBJECTIVE: We sought to determine the characteristics of "expanded access" and "compassionate use" programs registered in ClinicalTrials.gov and to determine the percentage of drugs provided through these programs that ultimately received FDA marketing approval. RESULTS: We identified 398 expanded access and compassionate use programs (hereafter referred to as expanded access programs) registered on ClinicalTrials.gov. Industry funded 61% (n = 241) of programs individually or collaboratively, while NIH and the US Federal Government rarely funded programs (3% [n = 11] and 2% [n = 6], respectively). Most programs provided access to drugs (71% [n = 282]), 11% to biologics (n = 43), and 10% to medical devices (n = 40). These programs covered 460 unique conditions, the most common being HIV (n = 26), leukemia (22), and multiple myeloma (n = 14). Only 2% of programs reported results in ClinicalTrials.gov. Most programs (82%) were open to enrolling adults and seniors (n = 326). These programs provided access to 210 unique experimental drugs, of which 76% have received FDA approval.
PMCID:5534121
PMID: 28754150
ISSN: 1756-0500
CID: 2654392

Shouldn't Dead Be Dead?: The Search for a Uniform Definition of Death

Lewis, Ariane; Cahn-Fuller, Katherine; Caplan, Arthur
In 1968, the definition of death in the United States was expanded to include not just death by cardiopulmonary criteria, but also death by neurologic criteria. We explore the way the definition has been modified by the medical and legal communities over the past 50 years and address the medical, legal and ethical controversies associated with the definition at present, with a particular highlight on the Supreme Court of Nevada Case of Aden Hailu.
PMID: 28661278
ISSN: 1748-720x
CID: 2614182